279 related articles for article (PubMed ID: 25114132)
1. Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis.
de Kock L; Sy SK; Rosenkranz B; Diacon AH; Prescott K; Hernandez KR; Yu M; Derendorf H; Donald PR
Antimicrob Agents Chemother; 2014 Oct; 58(10):6242-50. PubMed ID: 25114132
[TBL] [Abstract][Full Text] [Related]
2. N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosis.
Sy SK; de Kock L; Diacon AH; Werely CJ; Xia H; Rosenkranz B; van der Merwe L; Donald PR
Antimicrob Agents Chemother; 2015 Jul; 59(7):4129-38. PubMed ID: 25963985
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis.
van der Laan LE; Garcia-Prats AJ; Schaaf HS; Chirehwa M; Winckler JL; Mao J; Draper HR; Wiesner L; Norman J; McIlleron H; Donald PR; Hesseling AC; Denti P
Antimicrob Agents Chemother; 2022 Jun; 66(6):e0226421. PubMed ID: 35506699
[TBL] [Abstract][Full Text] [Related]
4. Para-aminosalicylic acid: the return of an old friend.
Donald PR; Diacon AH
Lancet Infect Dis; 2015 Sep; 15(9):1091-1099. PubMed ID: 26277036
[TBL] [Abstract][Full Text] [Related]
5. Probability of mycobactericidal activity of para-aminosalicylic acid with novel dosing regimens.
Abulfathi AA; Assawasuwannakit P; Donald PR; Diacon AH; Reuter H; Svensson EM
Eur J Clin Pharmacol; 2020 Nov; 76(11):1557-1565. PubMed ID: 32588106
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of Para-Aminosalicylic Acid and Its 2 Major Metabolites: A Potential Relationship to the Development of Gastrointestinal Intolerance.
Adams KT; Donald PR; Abulfathi AA; Diacon AH; Stander MA; Reuter H
J Clin Pharmacol; 2020 Apr; 60(4):489-494. PubMed ID: 31682027
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients.
Alffenaar JW; van Altena R; Harmelink IM; Filguera P; Molenaar E; Wessels AM; van Soolingen D; Kosterink JG; Uges DR; van der Werf TS
Clin Pharmacokinet; 2010 Aug; 49(8):559-65. PubMed ID: 20608757
[TBL] [Abstract][Full Text] [Related]
8. Dose regimen of para-aminosalicylic acid gastro-resistant formulation (PAS-GR) in multidrug-resistant tuberculosis.
Kibleur Y; Brochart H; Schaaf HS; Diacon AH; Donald PR
Clin Drug Investig; 2014 Apr; 34(4):269-76. PubMed ID: 24488376
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting.
Gandhi NR; Andrews JR; Brust JC; Montreuil R; Weissman D; Heo M; Moll AP; Friedland GH; Shah NS
Int J Tuberc Lung Dis; 2012 Jan; 16(1):90-7. PubMed ID: 22236852
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
Bhatt NB; Barau C; Amin A; Baudin E; Meggi B; Silva C; Furlan V; Grinsztejn B; Barrail-Tran A; Bonnet M; Taburet AM;
Antimicrob Agents Chemother; 2014 Jun; 58(6):3182-90. PubMed ID: 24663014
[TBL] [Abstract][Full Text] [Related]
11. Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old.
Kwara A; Yang H; Antwi S; Enimil A; Gillani FS; Dompreh A; Ortsin A; Opoku T; Bosomtwe D; Sarfo A; Wiesner L; Norman J; Alghamdi WA; Langaee T; Peloquin CA; Court MH; Greenblatt DJ
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397066
[TBL] [Abstract][Full Text] [Related]
12. Once-daily and twice-daily dosing of p-aminosalicylic acid granules.
Peloquin CA; Berning SE; Huitt GA; Childs JM; Singleton MD; James GT
Am J Respir Crit Care Med; 1999 Mar; 159(3):932-4. PubMed ID: 10051275
[TBL] [Abstract][Full Text] [Related]
13. A five-year review of prevalence and treatment outcomes of pre-extensively drug-resistant plus additional drug-resistant tuberculosis in the Henan Provincial Tuberculosis Clinical Medicine Research Centre.
Li Z; Liu F; Chen H; Han Y; You Y; Xie Y; Zhao Y; Tan J; Guo X; Cheng Y; Wang Y; Li J; Cheng M; Xia S; Niu X; Wei L; Wang W
J Glob Antimicrob Resist; 2022 Dec; 31():328-336. PubMed ID: 36210030
[TBL] [Abstract][Full Text] [Related]
14. Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis.
Svensson EM; Aweeka F; Park JG; Marzan F; Dooley KE; Karlsson MO
Antimicrob Agents Chemother; 2013 Jun; 57(6):2780-7. PubMed ID: 23571542
[TBL] [Abstract][Full Text] [Related]
15. HIV coinfection among multidrug resistant and extensively drug resistant tuberculosis patients--a trend.
Rajasekaran S; Chandrasekar C; Mahilmaran A; Kanakaraj K; Karthikeyan DS; Suriakumar J
J Indian Med Assoc; 2009 May; 107(5):281-2, 284-6. PubMed ID: 19886382
[TBL] [Abstract][Full Text] [Related]
16. Effect of Antiretroviral Therapy on Treatment Outcomes in a Prospective Study of Extensively Drug-Resistant Tuberculosis (XDR-TB) HIV Coinfection Treatment in KwaZulu-Natal, South Africa.
Yuengling KA; Padayatchi N; Wolf A; Mathema B; Brown T; Horsburgh CR; OʼDonnell MR
J Acquir Immune Defic Syndr; 2018 Dec; 79(4):474-480. PubMed ID: 30212394
[TBL] [Abstract][Full Text] [Related]
17. Variation in missed doses and reasons for discontinuation of anti-tuberculosis drugs during hospital treatment for drug-resistant tuberculosis in South Africa.
Pietersen E; Anderson K; Cox H; Dheda K; Bian A; Shepherd BE; Sterling TR; Warren RM; van der Heijden YF
PLoS One; 2023; 18(2):e0281097. PubMed ID: 36780443
[TBL] [Abstract][Full Text] [Related]
18. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis.
van Rijn SP; van Altena R; Akkerman OW; van Soolingen D; van der Laan T; de Lange WC; Kosterink JG; van der Werf TS; Alffenaar JW
Eur Respir J; 2016 Apr; 47(4):1229-34. PubMed ID: 26743484
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB.
Ghimire S; Van't Boveneind-Vrubleuskaya N; Akkerman OW; de Lange WC; van Soolingen D; Kosterink JG; van der Werf TS; Wilffert B; Touw DJ; Alffenaar JW
J Antimicrob Chemother; 2016 Oct; 71(10):2691-703. PubMed ID: 27231277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
